Literature DB >> 34352201

Prevalence and Predictors of Persistence of COVID-19 Symptoms in Older Adults: A Single-Center Study.

Matteo Tosato1, Angelo Carfì1, Ilaria Martis1, Cristina Pais1, Francesca Ciciarello1, Elisabetta Rota1, Marcello Tritto1, Andrea Salerno1, Maria Beatrice Zazzara1, Anna Maria Martone1, Annamaria Paglionico1, Luca Petricca1, Vincenzo Brandi1, Gennaro Capalbo1, Anna Picca1, Riccardo Calvani2, Emanuele Marzetti3, Francesco Landi3.   

Abstract

OBJECTIVES: Symptom persistence weeks after laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) clearance is a relatively common long-term complication of Coronavirus disease 2019 (COVID-19). Little is known about this phenomenon in older adults. The present study aimed at determining the prevalence of persistent symptoms among older COVID-19 survivors and identifying symptom patterns.
DESIGN: Cross-sectional study. SETTING AND PARTICIPANTS: We analyzed data collected in people 65 years and older (n = 165) who were hospitalized for COVID-19 and then admitted to the Day Hospital Post-COVID 19 of the XXX between April and December 2020. All patients tested negative for SARS-CoV-2 and met the World Health Organization criteria for quarantine discontinuation. MEASURES: Patients were offered multidisciplinary individualized assessments. The persistence of symptoms was evaluated on admission using a standardized questionnaire.
RESULTS: The mean age was 73.1 ± 6.2 years (median 72, interquartile range 27), and 63 (38.4%) were women. The average time elapsed from hospital discharge was 76.8 ± 20.3 days (range 25-109 days). On admission, 137 (83%) patients reported at least 1 persistent symptom. Of these, more than one-third reported 1 or 2 symptoms and 46.3% had 3 or more symptoms. The rate of symptom persistence was not significantly different when patients were stratified according to median age. Compared with those with no persistent symptoms, patients with symptom persistence reported a greater number of symptoms during acute COVID-19 (5.3 ± 3.0 vs 3.3 ± 2.0; P < .001). The most common persistent symptoms were fatigue (53.1%), dyspnea (51.5%), joint pain (22.2%), and cough (16.7%). The likelihood of symptom persistence was higher in those who had experienced fatigue during acute COVID-19. CONCLUSIONS AND IMPLICATIONS: Persistent symptoms are frequently experienced by older adults who have been hospitalized for COVID-19. Follow-up programs should be implemented to monitor and care for long-term COVID-19-related health issues.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; aging; fatigue; geriatrics; long COVID

Year:  2021        PMID: 34352201     DOI: 10.1016/j.jamda.2021.07.003

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   4.669


  13 in total

1.  Prevalence of and Factors Associated With Post-Coronavirus Disease 2019 (COVID-19) Condition in the 12 Months After the Diagnosis of COVID-19 in Adults Followed in General Practices in Germany.

Authors:  Karel Kostev; Lee Smith; Ai Koyanagi; Louis Jacob
Journal:  Open Forum Infect Dis       Date:  2022-07-04       Impact factor: 4.423

Review 2.  Long COVID-19: The Need for an Interdisciplinary Approach.

Authors:  Isabel Rodriguez-Sanchez; Leocadio Rodriguez-Mañas; Olga Laosa
Journal:  Clin Geriatr Med       Date:  2022-03-21       Impact factor: 3.529

3.  COVID-19 in the Geriatric Patient.

Authors:  Francesco Landi
Journal:  Clin Geriatr Med       Date:  2022-05-08       Impact factor: 3.529

4.  Effects of a New Multicomponent Nutritional Supplement on Muscle Mass and Physical Performance in Adult and Old Patients Recovered from COVID-19: A Pilot Observational Case-Control Study.

Authors:  Francesco Landi; Anna Maria Martone; Francesca Ciciarello; Vincenzo Galluzzo; Giulia Savera; Riccardo Calvani; Anna Picca; Emanuele Marzetti; Matteo Tosato
Journal:  Nutrients       Date:  2022-05-31       Impact factor: 6.706

Review 5.  Clinical patterns of somatic symptoms in patients suffering from post-acute long COVID: a systematic review.

Authors:  Nhu Ngoc Nguyen; Van Thuan Hoang; Thi Loi Dao; Pierre Dudouet; Carole Eldin; Philippe Gautret
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-02-10       Impact factor: 5.103

Review 6.  Caring for older adults during the COVID-19 pandemic.

Authors:  Virginie Prendki; Giusy Tiseo; Marco Falcone
Journal:  Clin Microbiol Infect       Date:  2022-03-11       Impact factor: 13.310

Review 7.  Social Media Efficacy in Crisis Management: Effectiveness of Non-pharmaceutical Interventions to Manage COVID-19 Challenges.

Authors:  Yunye Zhou; Anca Draghici; Jaffar Abbas; Riaqa Mubeen; Maria Elena Boatca; Mohammad Asif Salam
Journal:  Front Psychiatry       Date:  2022-02-07       Impact factor: 4.157

Review 8.  Post-acute Sequelae in COVID-19 Survivors: an Overview.

Authors:  Adekunle Sanyaolu; Aleksandra Marinkovic; Stephanie Prakash; Anne Zhao; Vyshnavy Balendra; Nafees Haider; Isha Jain; Teodora Simic; Chuku Okorie
Journal:  SN Compr Clin Med       Date:  2022-04-06

Review 9.  COVID-19 in Joint Ageing and Osteoarthritis: Current Status and Perspectives.

Authors:  Marianne Lauwers; Manting Au; Shuofeng Yuan; Chunyi Wen
Journal:  Int J Mol Sci       Date:  2022-01-10       Impact factor: 5.923

10.  Clinical course and risk factors for severe COVID-19 among Italian patients with cystic fibrosis: a study within the Italian Cystic Fibrosis Society.

Authors:  Carla Colombo; Marco Cipolli; Valeria Daccò; Paola Medino; Federico Alghisi; Maura Ambroni; Raffaele Badolato; Fiorella Battistini; Elisabetta Bignamini; Rosaria Casciaro; Fabiana Ciciriello; Mirella Collura; Isabella Comello; Michela Francalanci; Francesca Ficili; Anna Folino; Salvatore Leonardi; Giuseppina Leonetti; Maria Cristina Lucanto; Francesca Lucca; Massimo Maschio; Valeria Mencarini; Barbara Messore; Giovanna Pisi; Giovanna Pizzamiglio; Piercarlo Poli; Valeria Raia; Luca Riberi; Mirco Ros; Novella Rotolo; Angela Sepe; Giovanni Taccetti; Pamela Vitullo; Gianfranco Alicandro
Journal:  Infection       Date:  2021-12-07       Impact factor: 7.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.